Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment

In this study, we found that anti-PD-L1/VEGF combination therapy failed to activate tumor immunity in a syngeneic Egfr-mutant lung cancer mouse model. Unlike the combination of paclitaxel (PTX) and anti-PD-L1, the combination of PTX and anti-VEGF enhanced anti-tumor effects and altered the tumor microenvironment (TME), showing potential to activate anti-tumor immunity.

To investigate these mechanisms, we profiled the transcriptomes of tumors treated with PTX and/or anti-VEGF. The data suggested a potential trend where the combination of PTX and anti-VEGF therapy might be associated with a modest increase in natural killer (NK) cell populations within the TME.